PRIVACY ALERT: Marlboro-Chesterfield Pathology, P.C. Under Investigation for Data Breach of Over 235,000 Patient Records
SOURCE Schubert Jonckheer & Kolbe LLP
SAN FRANCISCO, July 2, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a data breach impacting the sensitive personal and health information of 235,911 patients of Marlboro-Chesterfield Pathology (MCP), a North Carolina-based full-service anatomic pathology lab.
On May 9, 2025, MCP publicly disclosed to the U.S. Department of Health and Human Services that it had experienced a data breach involving unauthorized access to its internal IT systems. According to a notice published by MCP on its website, the company discovered unauthorized activity on some internal IT systems on January 16, 2025.
Although the breach occurred in January, MCP did not begin notifying impacted patients until on or around May 9, 2025, which may have violated state and federal laws. The company recently informed patients that the following personal and health information may have been stolen in the breach: names, health insurance information, dates of birth, and medical treatment information.
If your personal information was impacted by this incident, you may be at risk of identity theft and other serious violations of your privacy. As a result, you may be entitled to money damages and an injunction requiring changes to MCP's cybersecurity practices.
If you received notification of this data breach or are a patient of MCP and wish to obtain additional information about your legal rights, please contact us today or visit our website at https://www.classactionlawyers.com/mcp.
About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco, and with the help of co-counsel, litigates cases nationwide.
Contact
Sonum Dixit
Schubert Jonckheer & Kolbe LLP
[email protected]
Tel: 415-299-8207
View original content:
©PR Newswire. All Rights Reserved.
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
